Under 21 CFR 812, significant-risk device studies require an approved IDE and IRB approval before they can begin. Non-significant-risk device studies follow abbreviated requirements but still need IRB approval and informed consent.
IDE studies must follow GCP-equivalent requirements and report unanticipated adverse device effects promptly.